Last updated: October 5, 2020
Sponsor: Massachusetts General Hospital
Overall Status: Completed
Phase
3
Condition
Vascular Diseases
Dizzy/fainting Spells
Circulation Disorders
Treatment
N/AClinical Study ID
NCT01531959
2011P002049
2018P000162
2015-098
Ages > 18 All Genders
Study Summary
Eligibility Criteria
Inclusion
Inclusion Criteria:
- At least 18 years of age
- Admitted to the SICU
- Requiring IV vasopressors at a rate of less than 100 mcg/min of phenylephrine, or 8mcg/min of norepinephrine, or 60 mcg/min of metaraminol; and unable to wean for morethan 24 hours while still maintaining desired blood pressure goal
Exclusion
Exclusion Criteria:
- Inadequate tissue oxygenation
- Liver failure
- Renal failure
- Hypovolemic shock or hypotension due to adrenal insufficiency
- Pregnancy
- Severe organic heart disease
- Urinary retention
- Pheochromocytoma
- Thyrotoxicosis
- Midodrine as pre-admission medication
- Any known allergies to midodrine
- Enrollment in another clinical trial
Study Design
Total Participants: 139
Study Start date:
April 01, 2012
Estimated Completion Date:
June 30, 2019
Study Description
Connect with a study center
Sir Charles Gairdner Hospital
Nedlands, Western Australia 60009
AustraliaSite Not Available
Beth Israel Deaconess Medical Center
Boston, Massachusetts 02215
United StatesSite Not Available
Massachusetts General Hospital
Boston, Massachusetts 02114
United StatesSite Not Available
Not the study for you?
Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.